The week of 4-8 November 2024 is set aside to celebrate the work of nearly 1 million trustees volunteering for charities across the UK. Trustees are individuals responsible for the
METUPUK are delighted for the approval of Trastuzumab deruxtecan (Enhertu) for second line use.
METUPUK are delighted for the approval of Trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults who have received one or more prior anti-HER2 based therapies approved for use through the Cancer Drugs Fund in NHS in England.
What does METUPUK do?
METUPUK is now 5 years old.
In those 5 years there haven’t been many changes in our plans from what we set out to do, but we have achieved so much! And we are now a registered charity!
Our strategy, aims and objectives are the same as when we started, we knew what direction we were going in but we are now looking to demand more action and accountability for patients.
METUPUK Announces Charity Status
METUPUK are very proud to announce their registration with the Charity Commission, marking an important new chapter for the UK’s only metastatic breast cancer advocacy group.
Response to @MattHancock re ‘fast-tracking transformative treatments’
METUPUK are looking for ACTION not just words on this new initiative that was released last week by Matt Hancock the Health Secretary. I’m delighted the UK will be teaming
Members of MetUpUK descend on parliament
Terminal breast cancer patients descended on parliament last week. Armed with over 70,000 signatures, they demanded change for the tens of thousands in the UK living with the killer disease.